361 Capital’s BioTelemetry, Inc. BEAT Stock Holding History

361 Capital’s Portfolio BEAT Stock Details BEAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-40,166	Closed	-$2.52M	–	425
2019 Q1	$2.52M	Buy	40,166 +3,606	+10%	+$248K	0.44%	124
2018 Q4	$2.18M	Buy	36,560 +7,872	+27%	+$473K	0.45%	107
2018 Q3	$1.85M	Buy	+28,688	New	+$1.6M	0.4%	89

Other funds holding BEAT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

361 Capital's BEAT Position: Q2 2019 in Review

361 Capital sold out of BioTelemetry, Inc. (BEAT) in Q2 2019, closing a stake of 40,166 shares — an estimated $2.52M sold.

361 Capital first reported a position in BEAT in Q3 2018 and held it in 3 quarters. The position peaked at $2.52M in Q1 2019. 251 funds tracked by Wall St. Rank hold BEAT as of Q2 2019.

361 Capital reported no remaining BioTelemetry, Inc. position as of Q2 2019 after selling out during the quarter.
361 Capital sold 40,166 BioTelemetry, Inc. shares in Q2 2019, an estimated $2.52M.
361 Capital first reported a position in BioTelemetry, Inc. in Q3 2018 and held it in 3 quarters.
361 Capital's BioTelemetry, Inc. position peaked at $2.52M in Q1 2019.
251 funds tracked by Wall St. Rank held BioTelemetry, Inc. as of Q2 2019.

Based on 361 Capital's 13F filing for Q2 2019, filed 7 Aug 2019.